CRC

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, March 14, 2024
Research, U.S. FDA, Trastuzumab, Colorectal cancer, Patient, Food and Drug Administration, CML, Running, G&A, Disclosure, MBA, MBC, Therapy, Cancer, CRC, FDA, Food, Pharmaceutical industry

BOULDER, Colo., March 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the fourth quarter and full year ended December 31, 2023, provided updated guidance on parallel lead product candidates and highlighted pipeline progress.

Key Points: 
  • Research and development (R&D) expenses: R&D expenses were $17.9 million for the fourth quarter of 2023, compared to $8.2 million for the fourth quarter of 2022.
  • General and administrative (G&A) expenses: G&A expenses for the fourth quarter of 2023 were $4.8 million, compared to $2.0 million for the fourth quarter of 2022.
  • Net Loss: Enliven reported a net loss of $19.4 million for the fourth quarter of 2023, compared to a net loss of $9.6 million for the fourth quarter of 2022.
  • Total net loss for the full year 2023 was $71.6 million, compared to $37.7 million for the full year 2022.

Fight Colorectal Cancer Unites Over 200 Advocates in Washington, D.C. for the 18th Annual Call-on Congress Event

Retrieved on: 
Tuesday, March 12, 2024
JAMA, Colorectal cancer, Congress, Disease, Caregiver, Incidence, Ageing, Exact sciences, Research, Woman, Statistics, Survivor, CDC, CRC, Large intestine, Dairy

WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- In a powerful display of unity, Fight Colorectal Cancer (Fight CRC) is hosting the 18th Annual Call-on Congress event, bringing together over 200 colorectal cancer survivors, caregivers, and loved ones.

Key Points: 
  • WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- In a powerful display of unity, Fight Colorectal Cancer (Fight CRC) is hosting the 18th Annual Call-on Congress event, bringing together over 200 colorectal cancer survivors, caregivers, and loved ones.
  • This landmark advocacy initiative aims to elevate personal stories and press for increased funding and support to combat colorectal cancer (CRC) .
  • Colorectal cancer, encompassing colon and rectal cancers, stands as the second-leading cause of cancer deaths for both men and women combined in the United States.
  • Encouraging Members of Congress to Champion Colorectal Cancer : Advocates will call on their representatives to become champions for colorectal cancer, actively working to transform the statistics surrounding the disease by joining the Colorectal Cancer Caucus.

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Retrieved on: 
Tuesday, March 12, 2024
Health, Union, Congress, DNA, Standard of care, Cancer, UDH, CRC, German, Pharmaceutical industry

Mainz Biomed’s showcase at the UDH Congress underscores the Company’s dedication to bridging the latest in scientific research with the wide spectrum of healthcare practices.

Key Points: 
  • Mainz Biomed’s showcase at the UDH Congress underscores the Company’s dedication to bridging the latest in scientific research with the wide spectrum of healthcare practices.
  • ColoAlert®, Mainz Biomed’s flagship product, is a testament to the Company’s mission, providing a highly accurate, easy-to-use, at-home colorectal cancer (CRC) screening kit.
  • By presenting ColoAlert® at the UDH Congress, Mainz Biomed highlights the role of cutting-edge molecular diagnostics in enhancing comprehensive health strategies, demonstrating the synergy between technological innovation and patient-centric care.
  • For more details on Mainz Biomed’s participation in the UDH Congress and to learn about the Company’s innovative diagnostic solutions, please visit Mainz Biomed’s official website at mainzbiomed.com.

Incendia Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research 2024

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Pharmaceutical, Health, Oncology, TME, Orientation, Workflow, Tissue, Neoplasm, Research, Tumor microenvironment, CRC, Colorectal cancer

An end-to-end 3D spatial biology workflow, Alpenglow’s 3D I/O Pro™, was applied to colorectal cancer (CRC) tissues stained with nuclear and general protein fluorescent dyes to quantify lymphocyte density in tumor parenchyma and stroma and analyze collagen features, including orientation, within 3D regions of interest in the TME.

Key Points: 
  • An end-to-end 3D spatial biology workflow, Alpenglow’s 3D I/O Pro™, was applied to colorectal cancer (CRC) tissues stained with nuclear and general protein fluorescent dyes to quantify lymphocyte density in tumor parenchyma and stroma and analyze collagen features, including orientation, within 3D regions of interest in the TME.
  • The ratio of stromal to parenchymal lymphocytes (lymphocyte infiltration ratio) varied from 1.4 up to 9.1 in 3D volumes and 1 to 25 in 2D virtual sections taken throughout all 5 CRC samples.
  • Qualitatively, areas with perpendicular collagen had more lymphocyte infiltration into the tumor parenchyma than areas with parallel collagen orientation.
  • This work highlights how the 3D I/O Pro™ workflow can characterize tumors based on complex spatial relationships within the tumor microenvironment, and could have broad applicability in research and development of novel cancer therapies that target tumor fibrosis or other features of the TME.

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...

Retrieved on: 
Monday, April 1, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lung cancer, BMY, NMPA, Development, NSCLC, Cetuximab, Progression-free survival, New Drug Application, Patient, Neoplasm, Shanda, NDA, Cancer, Bristol Myers Squibb, Pancreatic cancer, CRC, Safety, PFS, FDA, PDUFA, Pharmaceutical industry

The study remains ongoing to assess the additional key secondary endpoint of overall survival.

Key Points: 
  • The study remains ongoing to assess the additional key secondary endpoint of overall survival.
  • Results of the confirmatory trial showed that KRAZATI demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to standard-of-care chemotherapy as a second-line or later treatment for these patients.
  • KRAZATI had no new safety signals and the safety data was consistent with the known safety profile.
  • Zai Lab thanks the patients and investigators involved in the KRYSTAL-12 clinical trial.

Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…

Retrieved on: 
Thursday, March 28, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Civil service commission, BMY, NSCLC, Cetuximab, Progression-free survival, Patient, Neoplasm, Shanda, Health care, News, Bristol Myers Squibb, MHRA, Pancreatic cancer, CRC, Safety, European Commission, PFS, PDUFA, Medication, Pharmaceutical industry

The study remains ongoing to assess the additional key secondary endpoint of overall survival.

Key Points: 
  • The study remains ongoing to assess the additional key secondary endpoint of overall survival.
  • Results of the confirmatory trial showed that KRAZATI demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to standard-of-care chemotherapy as a second-line or later treatment for these patients.
  • “Today’s news is an important reinforcement of the power of a targeted therapy for patients with locally advanced or metastatic KRASG12C-mutated lung cancer.
  • Bristol Myers Squibb thanks the patients and investigators involved in the KRYSTAL-12 clinical trial.

California Resources Corporation Announces the Nomination of Christian S. Kendall to Its Board of Directors

Retrieved on: 
Tuesday, March 19, 2024
Oil, Gas, Alternative Energy, Energy, Other Energy, Utilities, American Heart Association, Natural gas, Growth, Shareholder, Triple accreditation, Harvard Business School, California Resources Corporation, Mobil, Advanced Management Program, Engineering, Noble Energy, Senior, Carbon, National Petroleum Council, CRC, CTV, Management

California Resources Corporation (NYSE: CRC) announced today that the Board of Directors has nominated Christian S. (Chris) Kendall to stand for election as a director at CRC’s 2024 Annual Meeting of Stockholders.

Key Points: 
  • California Resources Corporation (NYSE: CRC) announced today that the Board of Directors has nominated Christian S. (Chris) Kendall to stand for election as a director at CRC’s 2024 Annual Meeting of Stockholders.
  • “Mr.
  • Kendall has a strong and proven record of accomplishments in the new and always evolving energy sector,” added Tiffany (TJ) Thom Cepak, CRC’s Chair of the Board of Directors.
  • Prior to that, Mr. Kendall served in several other executive and management roles of increasing responsibility with Noble beginning in 2001.

Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer

Retrieved on: 
Monday, March 18, 2024
Science, Other Science, Biometrics, Biotechnology, Oncology, Health, Genetics, Clinical Trials, ACT, Cordeliers, Survival, Colorectal cancer, Patient, DNA, Observation, Standard of care, Doctor of Philosophy, MD, FOLFOX, Gastroenterology, Circulating tumor DNA, NTRA, CRC, MRD, Neoplasm, Nursing

The study’s main objective is to determine the benefit of adjuvant chemotherapy (ACT) in stage II CRC patients with detectable circulating tumor DNA (ctDNA) post-surgery.

Key Points: 
  • The study’s main objective is to determine the benefit of adjuvant chemotherapy (ACT) in stage II CRC patients with detectable circulating tumor DNA (ctDNA) post-surgery.
  • Patients who are Signatera MRD-positive will be randomized to receive ACT (FOLFOX 6m) or pursue observation (no chemotherapy).
  • While the Japanese and U.S. trials evaluate the benefit of MRD-guided treatment in stage III and high-risk stage II CRC patients, the French trial is focused on stage II CRC.
  • “We believe this randomized study could establish a new standard of MRD-guided care in stage II colorectal cancer, potentially improving treatment decisions for thousands of patients.”
    Natera has joined the study in progress.

Agenus Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Oncology, OS, BOT, Colitis, Inc., Colorectal cancer, PD, RECIST, IST, Partnership, RAS, Patient, MSI, FOLFIRINOX, BMS, Melanoma, MSS, BAL, Cancer, CRC, NLM, TIGIT, Liver disease, Pharmaceutical industry

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

Key Points: 
  • Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.
  • “In 2023, Agenus made significant advances across our BOT/BAL development program.
  • $25 million milestone payment from BMS triggered by the commencement of a Phase 2 study with BMS-986442 in December 2023.
  • For the fourth quarter ended December 31, 2023, we recognized revenue of $84 million and incurred a net loss of $49 million or $0.13 per share.

Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine

Retrieved on: 
Wednesday, March 13, 2024
Health, Oncology, Clinical Trials, Medical Supplies, Harvard Medical School, Colonoscopy, Colorectal cancer, Helmy Eltoukhy, Survival rate, Massachusetts General Hospital, Cancer, Risk, Patient, Ageing, Evaluation, American Cancer Society, Neoplasm, Perception, DNA, MD, Circulating tumor DNA, Hospital, PMA, CRC, Large intestine, Multimedia, FDA, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240313547689/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240313547689/en/
    Shield (TM) from Guardant Health is a blood test for colorectal cancer screening for adults age 45-84 who are at average risk.
  • (Photo: Business Wire)
    “Over 50 million eligible Americans do not get recommended screenings for colorectal cancer, partly because current screening methods are inconvenient or unpleasant,” said AmirAli Talasaz, Guardant Health co-CEO.
  • The Shield test detects colorectal cancer signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA).
  • One recent study showed that CRC screening rates tripled among adults who had declined prior CRC screening when they were offered Shield.